Cutting delays in reversing anticoagulation after intracerebral haemorrhage: three key changes at a UK comprehensive stroke centre

Adrian Parry-Jones
Salford Royal NHS Foundation Trust

Abstract

Prothrombin complex concentrate (PCC) reduces the risk of early haematoma expansion after intracerebral haemorrhage in patients taking vitamin K antagonists (VKA-ICH), so must be given without delay. We sought to identify and remove key barriers to rapid administration of PCC at our centre. We describe a single UK comprehensive stroke centre cohort study with mixed retrospective (1/1/2008 to 1/12/2010) and prospective (1/12/2010 to 31/7/2014) participant identification and a survey of UK stroke physicians. Seven hundred and thirteen ICH patients were admitted during the study period. Sixty nine of these patients were VKA-ICH. Patients not admitted on the acute stroke pathway (n=8) or who had palliative care commenced immediately on admission (n=6) were excluded, leaving 55 patients in the final analysis. During 2011/12 we identified and implemented service changes to reduce delays in PCC administration. The primary outcome was the time interval between diagnostic brain scan and commencement of PCC treatment (scan-to-needle time).

Secondary outcomes were the time interval between admission and commencement of PCC (door-to-needle time) and symptom onset and commencement of PCC (onset-to-needle time). Three key barriers were identified to rapid administration of PCC, including haematology consultation, collection of PCC from the transfusion laboratory, and obtaining the laboratory INR result. Our survey indicated that these barriers existed at most UK centres. We implemented point-of-care INR testing, moved PCC to the emergency department, and agreed a protocol to administer PCC autonomously. Our scan-to-needle time more than halved, from a median of 127 min (interquartile range (IQR), 111 to 208 min) prior to service changes to 58 min (IQR 50 to 91 min; p<0.001) afterwards. We have substantially reduced delays in delivering PCC to VKA-ICH patients at our centre and our simple changes could be easily implemented at centres facing similar barriers.

Problem

In patients with acute intracerebral haemorrhage (ICH) taking vitamin K antagonists (VKA; eg warfarin), rapid administration of prothrombin complex concentrate (PCC), and vitamin K is associated with a reduction in further haematoma expansion and may improve survival and functional outcomes. Given the focus on administering intravenous thrombolysis rapidly to acute ischaemic stroke patients, stroke services in the UK should be well placed to administer PCC to ICH patients in a similar time frame. However, we noted that ‘door-to-needle’ times (DNT) at our centre were much greater for delivering PCC than for delivering intravenous thrombolysis.

We thus sought to identify barriers to the rapid administration of PCC at our centre and to determine whether these barriers were widespread in UK practice. Prior to any service changes (1/1/2008 to 1/12/2010), the key processes in reversing anticoagulation following diagnosis of ICH (figure 1) were laboratory measurement of the international normalised ratio (INR), discussion of each case with the on-call haematologist for approval to use PCC, ordering PCC from blood transfusion, presenting the order form and PCC prescription to the blood transfusion laboratory (a five minute walk from the emergency department (ED)), collection and return of PCC, and reconstitution and administration of PCC to the patient in the ED.

Background

The incidence of ICH in patients taking oral anticoagulants is rising, partly due to their increased use for the prevention of ischaemic stroke in patients with atrial fibrillation.[1] Anticoagulant-associated ICH carries a particularly poor prognosis, with a case-fatality of up to 50% at three months.[2] Clinically significant haematoma expansion affects a third of all ICH patients and the risk is doubled by anticoagulants.[3] In patients taking a VKA, intravenous replacement of clotting factors and administration of vitamin K rapidly normalise the INR and may reduce haematoma expansion and improve survival.[4-7] PCC achieves this quicker than fresh frozen plasma,[8] so is recommended as first line treatment in the UK.[9]

Given the high risk of haematoma expansion in the first few hours after onset in ICH patients on VKAs (VKA-ICH), it is imperative that PCC is given without delay to maximise therapeutic effect. A large observational study of 853 VKA-ICH patients receiving PCC at 19 German centres has been recently published, demonstrating that treatment within four hours of admission to hospital is associated with a significant reduction in haematoma enlargement, when compared to more delayed treatment (19.8% vs. 41.5%).[7] This confirms the rationale for our focus on speed of administration.

Baseline measurement
In December 2010, we retrospectively identified all vitamin K antagonists (VKA-ICH) cases who presented to our centre via the acute stroke pathway from 1/1/2008 to 1/12/2010 and who were not immediately palliated in the emergency department (ED). VKA-ICH cases were identified by reviewing the electronic patient records (EPR) of all patients admitted to our hospital with a diagnosis of ICH. ICH cases were initially identified via the hospital coding department from 1/1/2008 to 30/4/2010 and from 1/5/2010 to 31/7/2014 via data collected for the Stroke Implementation National Audit Programme (SINAP) and subsequently the Sentinel Stroke National Audit Programme (SSNAP). Survival data were obtained from EPR. We collected clinical information, timings, laboratory results, imaging data (including haematoma volume by the ABC/2 method[10]) from EPR, radiology databases, and transfusion records. We defined the DNT for PCC as the time between arrival in hospital and commencement of PCC infusion.

All patients given PCC received Beriplex (CSL Behring UK Limited). Dosing was 20 IU/kg if the INR was ≤ 2.5 and 30 IU/kg if the INR was >2.5, as dictated by our hospital dosing protocol introduced by the haematology department from 9/10/2008. All patients given PCC also received intravenous vitamin K (10 mg). Upon completion of our initial retrospective analysis, we invited all members of the British Association of Stroke Physicians (BASP) (n=600) to participate in an online survey on 16/12/2010. All data are expressed as median and interquartile range. For the purposes of our analysis, patients were classified according to whether they were admitted before (‘pre’), during, or after (‘post’) implementation of the key service changes. Timings for patients before, during, and after service changes were compared using the Kruskal-Wallis test. All analyses were undertaken using SPSS (version 20, IBM Corp).

One hundred and ninety four ICH patients were admitted to our centre from 1/1/2008 to 1/12/2010 including 15 with VKA-ICH (table). Two were treated outwith the acute stroke pathway, leaving 13 cases included in our initial retrospective analysis. One patient did not receive PCC as the physician responsible felt it was not indicated. Three key delays were identified. First, the time from completion of investigations (computed tomography brain scan and INR) to ordering PCC from the transfusion lab was considerable (68 min; 44 to 81 min). Contacting and obtaining approval from the on-call haematologist was considered to be a major component of this delay. Second, an INR result is required to determine whether PCC should be given (indicated if INR ≥ 1.3). We found a median delay of 39 min (29 to 60 min) between admission and the registration of the INR on the lab computer system. Third, we found a delay of 18 min (14 to 31 min) from ordering to collecting PCC, and 43 min (15 to 63 min) from ordering to the start of PCC infusion.

We received 139 responses to our survey (139/600 invited BASP members; 23% response rate) with responses from all regions in the UK. The majority of respondents indicated that haematoology approval, the need to wait for a lab INR result, and storage of PCC away from the point-of-care were barriers at their centre. 76% reported that they must contact a haematologist to obtain PCC and 67% had to obtain the PCC from the haematology or transfusion lab. Only 5% had PCC available where they treat acute stroke patients. A point-of-care INR device was available to only 4% of respondents.

See supplementary file: ds5202.pdf - "Table and figures 1&2"

**Design**

We collected times for key processes in delivering PCC, identified barriers to rapid treatment, and implemented service changes between 25/1/2011 and 30/12/2012. VKA-ICH cases were prospectively identified from 1/12/2010 to 31/7/2014 to determine the impact of service changes. Three key delays were identified at our centre (Figure 1), including delay in obtaining an INR result, delays obtaining PCC from haematology, and delays seeking permission for the use of PCC from a haematologist. We thus engaged with haematology and blood transfusion to remove these barriers, by agreeing a shared protocol for the use of PCC in ICH and by moving a stock of PCC to the ED. We approached the Greater Manchester & Cheshire Cardiac & Stroke Network who agreed to fund provision of a point-of-care INR testing device to provide a rapid result to inform PCC administration and dosing.

**Strategy**

From 25/1/2011, stroke physicians were authorised to request and prescribe PCC without approval from a haematologist, provided treatment was concordant with a local protocol that was developed in collaboration with haematology. Once funding and approvals were obtained, we introduced a hand-held point-of-care INR testing device (Cooaguchek XS, Roche Diagnostics Limited) to the ED on 22/12/2011, which measures the INR in less than one minute. Finally, we obtained approval to introduce a stock of PCC in the ED from 30/12/2012.

**Results**

Between 25/1/2011 to 31/7/2014, 519 ICH cases were admitted including 54 with VKA-ICH. Of VKA-ICH cases, 6 were palliated on admission and 6 were outwith the acute stroke pathway, leaving 42 patients (19 during change implementation, 23 after) included in our final analysis. We found a marked reduction in our scan-to-needle time (Figure 2B) from 127 min (111 to 208 min; n=12) prior to service changes to 58 min (50 to 91 min; n=23; p<0.001) after changes were implemented, with a concomitant reduction in door-to-needle time (DNT) (218 min (141 to 289 min) ‘pre’ vs. 108 min (81 to 136 min) ‘post’; p<0.001). Onset-to-needle time improved but this was not statistically significant (308 min (243 to 770 min) ‘pre’ vs. 230 min (200 to 315 min) ‘post’; p=0.13). The improvement in DNT was partly accounted for by improvement in door-to-scan time of 18 min (48 min (27 to 75 min) ‘pre’ vs. 30 min (25 to 49) ‘post’; p=0.23). Improvement began during change implementation and was sustained for the 1.5 years afterwards.

**Lessons and limitations**

The administration of PCC to VKA-ICH patients represents an opportunity to give a treatment to improve the outcome for patients...
with an otherwise poor prognosis. Since completing our study, a large observational study has shown that treatment within four hours of admission to hospital is associated with a significant reduction in haematoma enlargement, when compared to more delayed treatment.[7] This confirms the rationale for our service changes, demonstrating that administering PCC within four hours of admission reduces the risk of haematoma expansion. By implementing point-of-care INR testing, developing a protocol to remove the need for haematology consultation and storage of PCC in the ED, we have more than halved the time taken to treat VKA-ICH patients at our centre. Prior to our service changes, 7/13 (54%) patients received PCC within four hours. During the period of service change this improved to 16/19 (84%). Following service changes, treatment within four hours was achieved for every patient (23/23; 100%). Given that treatment within four hours is associated with a reduction in haematoma growth, this improvement in the speed of delivery of PCC may translate to improved patient outcomes.

It is important to note that in April 2010 our centre became a regional comprehensive stroke centre, accepting patients directly from a catchment population of 2.68 million. The stroke service at our hospital had previously accepted patients from a considerably smaller catchment of around 250,000. This step change in working patterns and patient numbers is very likely to have impacted upon processes of care, but only 6 of the 13 patients included in the ‘pre-change’ group were admitted prior to service reconfiguration. Nevertheless, the clear improvement seen in door-to-scan time is likely to have been driven by the change to comprehensive stroke centre status and would be expected to partly account for the improvement in door-to-needle time. Onset-to-door times also showed a small, non-significant (p = 0.83) improvement from 149 min (67 to 853 min) ‘pre’ to 116 min (68 to 199 min) ‘post’, which will partly account for the non-significant improvement in onset-to-needle times. It is likely that the change in onset-to-needle time did not reach statistical significance due to the marked variation of onset-to-door times during the period prior to service change implementation. However, our primary finding of a marked and significant improvement in scan-to-needle time would be expected to be achieved largely by improvements in processes specific to delivery of PCC, rather than the general impact of change to comprehensive stroke centre status.

Conclusion

To further cut delays in giving PCC, we plan to implement prospective review of all VKA-ICH cases at stroke team meetings to improve staff awareness and identify any delays as they emerge. Awareness of the protocol for VKA-ICH treatment will also be incorporated in new staff induction. Although we have largely focused on DNT for our centre it is important to note that other factors may influence the efficacy of this treatment. Different preparations of PCC are available and vary from country to country, divided in to three or four factor PCCs, and there is evidence to suggest that four factor PCC is superior to three factor PCC in correcting the INR.[11] Also, it is important to ensure that an adequate dose is administered, as determined by the patient’s weight and their admission INR.[12] Newer anticoagulants have recently been licensed (e.g. rivaroxaban, dabigatran, apixaban) and although there is uncertainty about how to manage life-threatening bleeding with these agents,[11] it will still be necessary to attempt to normalise clotting as quickly as possible.

References

Declaration of interests

Competing Interests: None.

Acknowledgements

Lydia Baxter, Edith Wood, Martin Thomas, Andy Vail, Charles Sherrington, Pippa Tyrrell.

Ethical approval

Ethics committee approval: This work was done as part of a larger service development and research project which received NHS REC approval (11/H1011/3) and R&D from Salford R&D (2010/337 NEURO).
Table: Baseline characteristics of all patients with VKA-ICH presenting via the acute stroke pathway and not palliated on admission, divided by time period (pre-change, 1/1/2008 to 24/1/2011; during change, 25/1/2011 to 30/12/2012; post-change, 31/12/2012 to 31/7/2014).

<table>
<thead>
<tr>
<th></th>
<th>Pre-change (n=13)</th>
<th>During change (n=19)</th>
<th>Post-change (n=23)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age</td>
<td>80 (67 to 84)</td>
<td>77 (75 to 80)</td>
<td>78 (71 to 84)</td>
</tr>
<tr>
<td>Male sex</td>
<td>8 (62%)</td>
<td>11 (58%)</td>
<td>10 (43%)</td>
</tr>
<tr>
<td>GCS at admission</td>
<td>14 (10 to 15)</td>
<td>14 (11 to 15)</td>
<td>14 (12 to 15)</td>
</tr>
<tr>
<td>Baseline ICH volume, mL</td>
<td>28.4 (9.0 to 57.0)</td>
<td>23.0 (5.6 to 61.8)</td>
<td>8.3 (5.8 to 42.6)</td>
</tr>
<tr>
<td>Infratentorial location</td>
<td>0 (0%)</td>
<td>3 (16%)</td>
<td>1 (4%)</td>
</tr>
<tr>
<td>Intraventricular extension</td>
<td>3 (23%)</td>
<td>9 (47%)</td>
<td>10 (43%)</td>
</tr>
<tr>
<td>Lobar ICH</td>
<td>5 (38%)</td>
<td>5 (26%)</td>
<td>8 (35%)</td>
</tr>
<tr>
<td>INR at admission</td>
<td>3.0 (2.6 to 3.3)</td>
<td>2.9 (2.5 to 3.4)</td>
<td>3.1 (2.6 to 4.0)</td>
</tr>
<tr>
<td>INR after treatment*</td>
<td>1.3 (1.1 to 1.4); n=11</td>
<td>1.3 (1.2 to 1.3); n=17</td>
<td>1.4 (1.2 to 1.5); n=18</td>
</tr>
<tr>
<td>PCC given</td>
<td>12 (92%)</td>
<td>19 (100%)</td>
<td>23 (100%)</td>
</tr>
<tr>
<td>In-hours (0800 – 1700)</td>
<td>3 (23%)</td>
<td>12 (63%)</td>
<td>11 (48%)</td>
</tr>
<tr>
<td>30-day case-fatality</td>
<td>6 (46%)</td>
<td>10 (53%)</td>
<td>10 (43%)</td>
</tr>
</tbody>
</table>

*No post-treatment INR was available for patients who died shortly after treatment.

GCS, Glasgow Coma Scale; ICH, intracerebral haemorrhage; INR, international normalised ratio; PCC, prothrombin complex concentrate; VKA-ICH, vitamin K associated intracerebral haemorrhage. Data are shown as median (interquartile range) unless otherwise stated.
Figure 1: Flowchart describing steps involved in reversal of anticoagulation with prothrombin complex concentrate (PCC) before and after service changes designed to remove barriers to rapid treatment. The key changes we have introduced are: (1) point-of-care (POC) INR testing in the Emergency Department (ED); (2) removal of the need to contact the on-call Haematologist to obtain approval for the use of PCC; (3) storage of PCC in the ED for immediate availability; (4) delaying administration of vitamin K until the PCC infusion has commenced.
Figure 2: Times for key processes in administering PCC after VKA-ICH including (A) onset-to-needle time (ONT), (B) door-to-needle time (DNT), (C) scan-to-needle time (SNT), and (D) door to scan time. Data are shown for time intervals pre- (1/1/2008 to 24/1/2011, n=12), during (25/1/2011 to 30/12/2012, n=19), and post- (31/12/2012 to 31/7/2014, n=23) implementation of service changes.